表紙
市場調査レポート

EpiCast Report:非小細胞肺癌(NSCLC)の疫学的予測

EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2022

発行 GlobalData 商品コード 268834
出版日 ページ情報 英文 73 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
EpiCast Report:非小細胞肺癌(NSCLC)の疫学的予測 EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2022
出版日: 2013年03月31日 ページ情報: 英文 73 Pages
概要

世界の主要9ヶ国における非小細胞肺癌(NSCLC)の発症件数は、2012年の103万件から、2022年には126万件にまで拡大する(年間平均増加率2.2%)と予想されています。特に中国では、発症件数が55万件(2012年)から69万件(2022年)にまで増加すると推計されています。インドや日本でも今後10年間で発症件数が大きく増加するものと思われます。発症率増加の要因としては、高齢者人口の増加や喫煙者の増大、環境リスク要因の増加が挙げられます。

当レポートでは、世界の主要国における非小細胞肺癌(NSCLC)の発症状況と今後の見通しについて分析し、疾患の特徴や、現在の罹患・普及状況、今後10年間の発症件数の予測値などを調査・推計して、その結果を概略以下の内容でお届けいたします。

第1章 目次

第2章 イントロダクション

  • 概況
  • 関連調査

第3章 疫学

  • リスク要因と共存症
    • 喫煙者は非喫煙者よりも肺癌に感染しやすい
    • ラドンへの長期的被爆は肺癌リスクを高める
    • 各種がんの家族歴は、肺癌リスクの増大につながる
    • 結核(TB)は肺癌の感染リスク・死亡率を高める
    • COPD(慢性閉塞性肺疾患):肺癌の生存率低下につながる共存症
    • 肺癌検査プログラムは必ずしも有益ではない
    • 診断の段階が、肺癌の生存率に大きく影響する
  • 世界各国の動向
    • 米国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • 英国
    • 日本
    • 中国
    • インド
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の仮定・手法
  • 疫学的予測:今後10年間分
    • 発症率(全体)
    • 発症率(年齢層別)
    • 発症率(男女別)
    • 年齢調整された発症率
    • NSCLCの発症事例の分類
  • 議論
    • 分析の限界
    • 分析の強み

第4章 付録

図表一覧

目次
Product Code: GDHCER019

Summary

Lung cancer is a disease of uncontrolled cell growth in the lung tissues. It is one of the most commonly occurring cancers in the world, representing almost 13% of all cancers (Ferlay et al., 2010). NSCLC is the most common type of lung cancer, comprising about 85% of all lung cancers. An estimated 1.37 million new cases of NSCLC occurred worldwide in 2008 (Ferlay et al., 2010).

This forecast was built on an in-depth analysis of historical trends for lung cancer incidence, mortality, and survival; smoking prevalence, disease stage at diagnosis, and the status of lung cancer screening programs in each market.

GlobalData epidemiologists forecast that the number of incident cases of NSCLC in the 9MM will grow from 1.03 million cases in 2012 to 1.26 million by 2022 at a rate of 2.2% per year. The increase in the number of NSCLS incident cases is driven by changes in the incidence of lung cancer, an aging population, population growth, smoking habits in men and women, and exposure to environmental risk factors. Of the nine markets, China will have the highest number of incident cases of NSCLC, growing from 0.55 million cases in 2012 to 0.69 million by 2022 at a rate of 2.5% per year. In addition to China, India and Japan are also important markets for NSCLC in the next 10 years because these countries have a growing older population, a high smoking prevalence, and few smoking bans compared with western countries.

Scope

  • The NSCLC EpiCast Report provides overview of the risk factors and the global and historical trends for NSCLC in the nine major markets (9MM): US, France, Germany, Italy, Spain, UK, Japan, China, and India.
  • It also includes a 10-year epidemiology forecast of the diagnosed incident cases of NSCLC in these markets from 2012-2022.
  • The incident cases are further segmented by sex and age (40-49 years, 50-59 years, 60-69 years, 70-79 years, and at ages 80 years and older), cancer stage at diagnosis (AJCC Stage I-IV), cancer histological subtype (adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and others), and the proportion of smokers among NSCLC cases.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global NSCLC market.
  • Quantify patient populations in the global NSCLC market to improve product development, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying sex, age groups, and cancer histological subtypes that present the best opportunities for NSCLC therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Risk Factors and Comorbidities
    • 3.1.1. Smokers are more likely to have lung cancer than non-smokers
    • 3.1.2. Long-term exposure to radon increases the risk of lung cancer
    • 3.1.3. Family history of any cancer increases lung cancer risk
    • 3.1.4. TB increases the risk of lung cancer and increases mortality risk
    • 3.1.5. COPD is a comorbidity that reduces lung cancer survival
    • 3.1.6. Lung cancer screening programs may not be beneficial
    • 3.1.7. Stage at diagnosis significantly impacts the survival of lung cancer cases
  • 3.2. Global Trends
    • 3.2.1. US
    • 3.2.2. France
    • 3.2.3. Germany
    • 3.2.4. Italy
    • 3.2.5. Spain
    • 3.2.6. UK
    • 3.2.7. Japan
    • 3.2.8. China
    • 3.2.9. India
  • 3.3. Forecast Methodology
    • 3.3.1. Sources Used
    • 3.3.2. Sources Not Used
    • 3.3.3. Forecast Methods and Assumptions
  • 3.4. Epidemiology Forecast (2012-2022)
    • 3.4.1. Incident Cases of NSCLC
    • 3.4.2. Age-Specific Incident Cases of NSCLC
    • 3.4.3. Sex-Specific Incident Cases of NSCLC
    • 3.4.4. Age-Standardized Incidence Rates of NSCLC
    • 3.4.5. Segmentation of NSCLC Incident Cases
  • 3.5. Discussion
    • 3.5.1. Limitations of the Analysis
    • 3.5.2. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Epidemiology and Clinical Trials Analysis
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Contact Us
  • 4.6. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Lung Cancer
  • Table 2: 9MM, Age-Standardized (World) Smoking Prevalence, Men and Women, 2006 and 2009
  • Table 3: 9MM, Sources of NSCLC Incidence Data
  • Table 4: 9MM, Incident Cases of NSCLC, Men and Women Ages ≥40 Years, N, Selected Years 2012-2022
  • Table 5: 9MM, Incident Cases of NSCLC, by Age, Men and Women, N (Row %), 2012
  • Table 6: 9MM, Incident Cases of NSCLC, by Sex, Ages ≥40 Years, N (Row %), 2012
  • Table 7: 9MM, Incident Cases of NSCLC, by Stage at Diagnosis, Men and Women Ages ≥40 Years, N (Row %), 2012
  • Table 8: 9MM, Incident Cases of NSCLC, by Histological Subtype, Ages ≥40 Years, Men and Women, N (Row %) , 2012
  • Table 9: Comparison of GlobalData Forecast for Lung Cancer Incident Cases with Globocan 2008

List of Figures

  • Figure 1: 9MM, Age-Standardized (World) Lung Cancer Incidence, Men Ages ≥40 Years, 1993-2002
  • Figure 2: 9MM, Age-Standardized (World) Lung Cancer Incidence, Women Ages ≥40 Years, 1993-2002
  • Figure 3: Age-Standardized (US 2000) Lung Cancer Incidence and Mortality, Men and Women, All Ages, US, 1999-2008
  • Figure 4: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ≥40 Years, US, 1993-2008
  • Figure 5: Relative Risk of Death from Lung Cancer in Current Smokers, Men and Women, US
  • Figure 6: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ≥40 Years, France, 1993-2008
  • Figure 7: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ≥40 Years, Germany, 1993-2008
  • Figure 8: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ≥40 Years, Italy, 1993-2008
  • Figure 9: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ≥40 Years, Spain, 1991-2007
  • Figure 10: Age-Standardized (World) Lung Cancer Incidence and Mortality, Ages ≥40 Years, UK, 1993-2008
  • Figure 11: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ≥40 Years, Japan, 1993-2008
  • Figure 12: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ≥40 Years, China, 1993-2008
  • Figure 13: Age-Standardized (World) Lung Cancer Incidence, Men and Women Ages ≥40 Years, India, 1993-2002
  • Figure 14: 9MM, Incident Cases of NSCLC, Men and Women Ages ≥40 Years, N, Selected Years 2012-2022
  • Figure 15: 9MM, Incident Cases of NSCLC, by Sex, Ages ≥40 Years, N, 2012
  • Figure 16: 9MM, Age-Standardized (World) NSCLC Incidence, 2012
  • Figure 17: 9MM, Incident Cases of NSCLC, by Stage at Diagnosis, Men and Women Ages ≥40 Years, % and N, 2012
  • Figure 18: 9MM, Incident Cases of NSCLC by Histological Subtype, Men and Women Ages ≥40 Years, %, 2012
  • Figure 19: 9MM, Proportion of Smokers Among NSCLC Cases and the General Population, Men and Women, %, 2012
  • Figure 20: Smoking History in NSCLC Cases in the 9MM, Men and Women Ages ≥40 Years, N, 2012
Back to Top